|
| 全球及中国膀胱癌流行特征与疾病负担分析——基于GLOBOCAN 2022数据库 |
| Prevalence and Disease Burden of Bladder Cancer in China and Worldwide: Based on the GLOBOCAN 2022 Database |
| 投稿时间：2024-12-11 修订日期：2025-01-07 |
| DOI： |
|
 |
| 中文关键词: 膀胱肿瘤 GLOBOCAN 2022 发病率 死亡率 人类发展指数 |
| 英文关键词:bladder cancer GLOBOCAN 2022 ASIR ASMR HDI |
| 基金项目: |
|
| 摘要点击次数: 53 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 分析2022年全球不同地区与中国膀胱癌的流行病学特征和疾病负担，为进一步采取精准有效的防控措施提供理论依据及数据支撑。方法 膀胱癌发病率和死亡率的估算数据来自于GLOBOCAN 2022数据库，按不同地理区域、性别、年龄别、人类发展指数（Human Development Index, HDI）等级进行分组，分析发病数、死亡数、年龄标化发病率（Age-Standardized Incidence Rate, ASIR）和年龄标化死亡率（Age-Standardized Mortality Rate, ASMR）等指标，采用简单线性回归和Spearman相关系数检验研究HDI与ASIR、ASMR的相关性，并对历史发病率变化趋势及2050年预测数据进行分析。结果 2022年全球膀胱癌新发病例数为614298例，死亡病例数为220596例，ASIR和ASMR分别为5.6/10万和1.8/10万。欧洲地区ASIR和ASMR最高，分别为12.0/10万、3.0/10万。全球男性ASIR和ASMR均高于女性，均是女性的3.9倍。全球老龄人群的发病率和死亡率分别是劳动力人群的16.0倍和28.3倍。各地区HDI水平和膀胱癌的ASIR、ASMR呈正相关（r值分别为0.670、0.434，均P＜0.001）。中国膀胱癌男性发病率从2002年的7.7/10万小幅波动上升至2017年的8.0/10万，女性发病率基本持平（2002年为2.0/10万，2017年为1.9/10万），而美国呈下降趋势，日本则呈显著上升趋势。预测2050年，全球膀胱癌新发病例数达110.0万，比2022年增长79.2%；死亡病例增加到47.2万，增幅达113.6%；中国发病及死亡分别为17.6万和10.3万，增幅分别为89.2%和151.2%。结论 全球膀胱癌的疾病负担分布不均，与不同地理区域、性别、年龄、HDI等因素相关。伴随着人口老龄化形势加剧和工业化进程加快，我国膀胱癌发病和死亡风险进一步增大，膀胱癌的防治工作需进一步加强。 |
| 英文摘要: |
| Objective Prevention and control strategies should be targeted at different age groups by analyzing the incidence and mortality data in China and worldwide in 2022. Methods The incidence and mortality data of bladder cancer was obtained from the GlOBOCAN2022 database. They were grouped according to different geographical regions, sex, age, and human development index (HDI).We analyzed the incidences, deaths, age-standardized incidence rate(ASIR) and age-standardized mortality rate(ASMR) of bladder cancer. Simple linear regression and Spearman's correlation coefficient test were used to analysis the correlation between the human development index(HDI) and ASIR/ASMR, the trend of the historical incidence and the data in 2050. Results In 2022, the number of new cases and deaths of bladder cancer worldwide was 614298 and 220596, respectively, with ASIR and ASMR at 5.6 and 1.8 per 100,000. ASIR and ASMR in Europe were the highest , at 12.0 and 3.0 per 100,000, respectively. Globally, the ASIR and ASMR for males were 3.9 times higher than for females. Compared to the elderly, the incidence rate and mortality in working-age population were 16.0 and 28.3 times higher. A positive correlation was observed between HDI levels and ASIR and ASMR of bladder cancer. The incidence trend was decreasing in the US, while it was significantly increasing in Japan, and it was fluctuated slightly in China. The global incidence and mortality of bladder cancer will reach 1.100 million and 0.472 million by 2050. And they will be 0.176 million and 0.103 million in China. Conclusions There are significant differences in the burden of bladder cancer by region, sex, age and HDI levels. With the aggravation of population aging and the acceleration of industrialization, the risk of bladder cancer in China is further increased, and the prevention and treatment of bladder cancer needs to be strengthened. |
|
在线阅读
查看/发表评论 下载PDF阅读器 |
|
|
|